• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Modification of In Vivo Cardiac Performance by Intracoronary Gene Transfer of -Adrenergic Receptor Signaling Components

        互联网

        376
        Alterations in β-adrenergic receptor (βAR) signaling typically occur in cardiomyocytes from hearts progressing toward failure (1 ). Regulation of G-protein-coupled βARs mostly involves phosphorylation of agonist-occupied receptors by a βAR kinase (βARK1), leading to desensitization. This process also requires a second protein, β-arrestin, which binds to phosphorylated receptors and sterically interdicts further coupling. βARK1, also known as GRK2, is primarily a cytosolic enzyme that must translocate to the membrane in order to phosphorylate its receptor substrate. This is accomplished through a direct physical interaction between the GRK and the βγ-subunits of G-proteins (Gβγ ) (2 ,3 ). The Gβγ -binding site on βARK1 has been mapped to a region located toward the carboxyl terminus of the enzyme, and a peptide derived from this region (βARKct) can act as an effective in vivo βARK1 inhibitor. The βARKct represents the last 194 amino acids of βARK1 containing the Gβγ -binding domain (2 ) and has been utilized in transgenic mice to inhibit the in vivo activity of βARK1 (4 ). Moreover, these mice present with enhanced cardiac contractility that has led to the rescue of several mouse models of cardiomyopathy (4 ,5 ).
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序